CDK4 and breast cancer: Due to according references with synergistic efficacy of a combined inhibition of PI3K and CDK4/CDK6, e.g. in breast cancer models, manual curation suggested PI3K-inhibition in combination with palbociclib in case of PIK3CA mutation26.